SCHEMBL25284614

SCHEMBL25284614

N#Cc1cc(-c2cc(F)cc(C(=O)O)c2Cl)c[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 2/20 0.41
▸ CCNC P24863 2/20 0.38
▸ CDK8 P49336 2/20 0.38
▸ DYRK1A Q13627 1/20 0.36
▸ CYP3A4 P08684 1/20 0.33
▸ AURKA O14965 1/20 0.32
▸ TPX2 Q9ULW0 1/20 0.32
▸ PRKAB2 O43741 5/20 0.32
▸ PRKAG1 P54619 5/20 0.32
▸ PRKAA2 P54646 5/20 0.32
▸ PRKAA1 Q13131 5/20 0.32
▸ PRKAG3 Q9UGI9 5/20 0.32
▸ PRKAG2 Q9UGJ0 5/20 0.32
▸ PRKAB1 Q9Y478 5/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ CSNK2A2 P19784 1/20 0.31
▸ CSNK2B P67870 1/20 0.31
▸ CSNK2A1 P68400 1/20 0.31
▸ F7 P08709 1/20 0.31
▸ F3 P13726 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25233707 0.85 MGLL (0.41) MGLLCCNCCDK8KDM4E
SCHEMBL29746242 0.81 TSHR (0.41) CCNCCDK8DYRK1AAURKATPX2
SCHEMBL25238175 0.80 DYRK1A (0.46) MGLLDYRK1ACYP3A4PRKAB2PRKAG1
SCHEMBL25233661 0.77 MGLL (0.48) MGLLDYRK1ACYP3A4PRKAB2PRKAG1
SCHEMBL27432704 0.71 KEAP1 (0.38) CYP3A4KDM4ENOTUMKEAP1
SCHEMBL31055668 0.71 MGLL (0.48) MGLLDYRK1AAURKATPX2KDM4E
SCHEMBL29746180 0.69 SLC6A3 (0.43) CCNCCDK8
SCHEMBL29746142 0.68 CYP3A4 (0.36) DYRK1ACYP3A4PRKAB2PRKAG1PRKAA2
SCHEMBL21250750 0.66 NOTUM (0.40) DYRK1ACYP3A4NOTUMKEAP1
SCHEMBL9518431 0.66 CCNC (0.44) CCNCCDK8DYRK1AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2025-02-20 — — US disclosed
EP-4448522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2024-10-23 — — EP disclosed
CN-118488953-A Bicyclic heterocyclic compounds useful as monoacylglycerol lipase inhibitors 豪夫迈·罗氏有限公司 2024-08-13 — — CN disclosed
WO-2023110958-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250059185-A1 BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS MGLL, LIPC, PNLIP MGLL 1/4885CCNC 2649/4885CDK8 2883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback